ArticleDiscover oncology2025
Global research trends in CAR-T cell therapy for glioblastoma: a bibliometric and visualized analysis.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundGlioblastoma (GBM) is the most aggressive and lethal primary malignant brain tumor in adults, characterized by extensive heterogeneity and a profoundly immunosuppressive microenvironment. Despite advances in surgery, radiotherapy, and chemotherapy, therapeutic outcomes remain poor. Chimeric antigen receptor (CAR)-T cell therapy has shown remarkable efficacy in hematologic malignancies and is now being explored for solid tumors such as GBM. Given the expanding research landscape, a systematic understanding of global trends and hotspots in this domain is urgently needed.
methodsWe conducted a comprehensive bibliometric and visualized analysis of publications related to CAR-T cell therapy in GBM from inception to December 31, 2024, using the Web of Science Core Collection. CiteSpace was used to analyze publication trends, country and institutional collaboration, author impact, journal co-citation, reference networks, and keyword co-occurrence, clustering, and bursts.
resultsA total of 303 relevant publications were included. Annual outputs showed rapid growth beginning in 2015, with the United States and China leading in productivity and collaboration. Influential authors such as Christine E. Brown and Donald M. O'Rourke were identified as core contributors. Neuro-Oncology and Clinical Cancer Research emerged as key publishing and co-cited journals. Co-citation and keyword analysis revealed a shift from early focus on single-antigen CAR designs (e.g., IL13Rα2, EGFRvIII) toward dual-target constructs, "armored" CAR-T cells, and combinatorial immunotherapies. Recent research hotspots included immunomodulation, precision medicine, and novel delivery platforms such as nanoparticles and oncolytic viruses.
conclusionsThis study maps the evolving scientific landscape of CAR-T cell therapy in GBM, highlighting key contributors, institutional collaboration, and emerging research frontiers. The transition from basic antigen targeting to multifunctional, immune-enhancing strategies reflects a maturing field with increasing translational focus. Our findings offer valuable insights that can inform strategic funding allocation by identifying high-impact institutions and authors, optimize clinical trial design by highlighting emerging combinatorial and delivery strategies, and guide novel target discovery through analysis of co-cited references and keyword bursts. By revealing global collaboration networks and thematic shifts, this study also supports the development of interdisciplinary research frameworks in CAR-T therapy for GBM.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.